title: Selecting haematological malignancy patients for intravenous immunoglobulin.
abstract: Prior randomised studies of immunoglobulin replacement therapy have studied mixed populations with or without a history of infections. Immunoglobulin therapy is expensive and in limited supply suggesting that optimising patient selection is of value. In this retrospective study, infection history identified high-risk groups benefiting from treatment. A group of patients without any infection history had a low risk of infection without immunoglobulin.
authors.affiliation: Australian National University Medical School, Canberra, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Paxton
authors.affiliation: Australian National University Medical School, Canberra, Australia.|Department of Immunology, Canberra Hospital, Canberra, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Hawkins
authors.affiliation: Australian National University Medical School, Canberra, Australia. philip.crispin@act.gov.au.|Department of Haematology, Canberra Hospital, Canberra, Australia. philip.crispin@act.gov.au.
authors.forename: P
authors.initials: P
authors.lastname: Crispin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D016756:Immunoglobulins, Intravenous
keywords: haematological malignancy; infection; intravenous immunoglobulin